News and Updates

The FDA has approved a Phase II trial for ziresovir, a novel RSV fusion protein inhibitor. Learn how this breakthrough drug targets severe infections.

AstraZeneca has halted a major Phase 3 lung cancer trial after an independent review found the drug failed to meet primary efficacy goals. Learn more here.

TCS has introduced an Agentic AI platform to optimize drug development, using autonomous technology to accelerate discovery and improve clinical success.

New data reveals only 11% of sponsors and CROs have fully integrated AI into clinical trials. Discover the barriers to adoption in modern drug development.

New data reveals a rise in clinical trial site delays and Phase II terminations in 2025. Discover the key factors impacting drug development pipelines.

AbelZeta receives FDA IND clearance for Prizlon-cel to treat large B-cell lymphoma. Learn how this novel CAR-T therapy could transform oncology care.

JW Pharmaceutical’s Epaminurad shows superior efficacy in Phase III gout trials, offering a new treatment pathway for patients with chronic hyperuricemia.

New clinical research shows Zeus Hygia’s Metaberine® significantly improves metabolic health and glucose markers at a low 200 mg daily dose. Read more.

New clinical research shows Metaberine® improves metabolic health and insulin sensitivity with a low 200 mg daily dose. Read the study findings here.

Argenx reports successful Phase 3 trial results for Vyvgart in treating autoimmune myositis, marking a major milestone for this targeted FcRn inhibitor.